We have located links that may give you full text access.
Journal Article
Review
A review of contusugene ladenovec (Advexin) p53 therapy.
Current Opinion in Molecular Therapeutics 2009 Februrary
Contusugene ladenovec (Advexin; INGN-201; Introgen Therapeutics Inc) is a replication-impaired, non-integrating, serotype 5 adenoviral vector that carries the p53 gene under the control of the CMV promoter. Deletion or mutation of the p53 gene has been observed in approximately half of malignancies in patients with cancer and p53 pathway dysfunction was observed in the majority of others, thereby providing the rationale for p53 restoration in the treatment of cancer. Advexin has demonstrated a consistent safety profile and clinical efficacy as a monotherapy, as well as in combined modality regimens with chemotherapy and radiation. Additive or synergistic effects have been observed in a variety of tumor types, including NSCLC, squamous cell carcinoma of the head and neck, hepatocellular carcinoma, glioma, and breast, prostate and colorectal cancers. The identification of biomarkers may help direct research in tumor-specific therapeutics.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app